Nigerian health officials have issued a critical recall of a specific batch of Johnson & Johnson’s Benylin Paediatric cough syrup. The urgent action comes after tests revealed dangerously high levels of a potentially toxic substance in the medication.
Unacceptable Levels of Diethylene Glycol
The National Agency for Food and Drug Administration and Control (NAFDAC) announced the recall on Wednesday. Laboratory analysis of Benylin Paediatric discovered concerning amounts of diethylene glycol. This chemical has been linked to a series of tragic child deaths in multiple countries since 2022, raising serious safety concerns.
Diethylene glycol is a colorless, odorless liquid commonly used in antifreeze and industrial applications. However, accidental ingestion can be hazardous, leading to symptoms like abdominal pain, vomiting, diarrhea, headaches, and potentially causing acute kidney injury.
Product Details and Urgent Action
The specific Benylin Paediatric syrup under recall is used to treat coughs, congestion, hay fever, and other allergic reactions in children aged two to twelve. The affected batch was manufactured in South Africa in May 2021 and carries an expiry date of April 2024.
NAFDAC strongly advises anyone with bottles from this batch to immediately discontinue use and dispose of the syrup safely. Alternatively, they can return the bottles to their nearest NAFDAC office for proper disposal.
Johnson & Johnson has yet to comment on the recall, directing inquiries to Kenvue, the company that acquired the Benylin brand in a recent spin-off. As of now, Kenvue representatives have not responded to requests for comment.
The Nigerian cough syrup recall underscores the vital role of regulatory agencies in ensuring public health and safety. This incident also serves as a stark reminder for parents and caregivers to exercise extreme caution when administering medications to children. Always verify the medication’s expiry date and ensure it comes from a reputable source.
Looking Ahead: Ensuring Safe Medication
The Nigerian authorities are working diligently to contain the potentially harmful effects of this contaminated cough syrup. This situation emphasizes the need for stricter quality control measures throughout the entire pharmaceutical supply chain, from manufacturing to distribution. Additionally, improved international collaboration on medication safety protocols can help prevent similar incidents in the future.
Source: ReutersÂ
